Category: 132710-90-8

132710-90-8, 1-Boc-4-(3-hydroxypropyl)piperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Sodium hydride (12.5 mg, 0.3141 mmol) was added to a solution of tert-butyl 4-(3- hydroxypropyl)piperazine-1-carboxylate (154-1) (76.7 mg, 0.3141 mmol) in DMF (2.09 mL ) at 0 C. The bath was removed and the reaction stirred for 30 min. 6-(4-chlorophenyl)-8-(1-(3- chloropropyl)-1H-pyrazol-4-yl)-1-methylspiro[benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine-4,1′- cyclopropane] (89-1) (0.1 g, 0.2094 mmol) was added, the reaction stirred for 16 hours and concentrated. The product was purified by column chromatography (silica, 0-15% MeOH in DCM) to give tert-butyl 4-(3-(3-(4-(6-(4-chlorophenyl)-1- methylspiro[benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine-4,1′-cyclopropan]-8-yl)-1H-pyrazol-1- yl)propoxy)propyl)piperazine-1-carboxylate (154-2) (22.0 mg, 15.3 %) LC/MS (ES+): m/z 685.3 [M + H]+

132710-90-8, As the paragraph descriping shows that 132710-90-8 is playing an increasingly important role.

Reference：
Patent; C4 THERAPEUTICS, INC.; PHILLIPS, Andrew, J.; NASVESCHUK, Chris, G.; HENDERSON, James, A.; LIANG, Yanke; FITZGERALD, Mark, E.; MICHAEL, Ryan, E.; (790 pag.)WO2017/197056; (2017); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

132710-90-8, 1-Boc-4-(3-hydroxypropyl)piperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of tert-butyl 4-(3 -hydroxypropyl)piperazine- 1 -carboxylate (1.52 g, 6.2 mmol), Ph3P (2.46 g, 9.4 mmol), 12 (2.40 g, 9.4 mmol) and imidazole (1.28 g, 18.6 mmol) in DCM (100mL) was stirred at room temperature for 5 h and then diluted with DCM (200 mL). The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered and evaporated. The residue was purified by chromatography (PE : EtOAc = 5 : 1) to provide tert-butyl 4-(3- iodopropyl)piperazine- 1 -carboxylate (1 .10 g, 50%) as a colorless oil.

132710-90-8, As the paragraph descriping shows that 132710-90-8 is playing an increasingly important role.

Reference：
Patent; PRINCIPIA BIOPHARMA, INC.; VERNER, Erik; BRAMELD, Kenneth Albert; WO2015/120049; (2015); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.132710-90-8,1-Boc-4-(3-hydroxypropyl)piperazine,as a common compound, the synthetic route is as follows.

Triphenylphosphine (2.059 g, 7.85 mmol), tert-buty 4-(3-hydroxypropyl)piperazine-l- carboxylate (1.692 g, 6.93 mmol) and diisopropyl (E)-diazene-l,2-dicarboxylate (1.587 g, 7.85 mmol) were mixed in THF (20 mL) at 0 C, and then 4-chloro-3-hydroxy-5-nitrobenzamide (1 g, 4.62 mmol) was added. The reaction solution was maintained at RT for 16 hrs then the brown reaction solution was partitioned between sat. NaHC03 (aq) and EtOAc. The organic layer was washed with brine, dried over MgSCM, concentrated and purified on silica gel (20 %- 80 % (3:1 EtOAc/EtOH) / Hexane, with 2% NH4OH; 330 g RediSep column). Desired fractions were combined and concentrated to give the title compound as a white solid (970 mg, 47 % yield). *H NMR (400 MHz, DMSO-t) delta ppm 8.30 (s, 1 H), 8.05 (d, 3=1.77 Hz, 1 H), 7.88 (d, J=1.77 Hz, 1 H), 7.80 (s, 1 H), 4.28 (t, J=6.21 Hz, 2 H), 3.31 (br. s., 4 H), 2.48 (t, J=7.10 Hz, 2 H), 2.33 (t, J=4.94 Hz, 4 H), 1.96 (t, J=6.59 Hz, 2 H), 1.40 (s, 9 H). LCMS (LCMS Method K): Rt = 0.69 min, [M+H]+ = 443.4.

132710-90-8, As the paragraph descriping shows that 132710-90-8 is playing an increasingly important role.

Reference：
Patent; GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED; CHARNLEY, Adam Kenneth; DARCY, Michael G.; DODSON, Jason W.; DONG, Xiaoyang; HUGHES, Terry V.; KANG, Jianxing; LEISTER, Lara Kathryn; LIAN, Yiqian; LI, Yue; MEHLMANN, John F.; NEVINS, Neysa; RAMANJULU, Joshi M.; ROMANO, Joseph J.; WANG, Gren Z.; YE, Guosen; ZHANG, Daohua; (451 pag.)WO2017/175147; (2017); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.132710-90-8,1-Boc-4-(3-hydroxypropyl)piperazine,as a common compound, the synthetic route is as follows.

2-Chloro-1-fluoro-4-nitrobenzene (320 mg) and sodium hydride (60% in oil, 83 mg) were added to a THF (3 mL) solution of tert-butyl 4-(3-hydroxypropyl)piperazine-1-carboxylate (310 mg) at room temperature, and the reaction mixture was stirred at 70C overnight. Water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with water and saturated brine, was dried over sodium sulfate, and was then concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (eluent: hexane-ethyl acetate) to obtain the target compound. 1H-NMR (CDCl3) delta 1.46 (9H, s), 1.94-2.04 (2H, m), 2.36-2.44 (4H, m), 2.51 (2H, t, J = 7.1 Hz), 3.44 (4H, br-s), 4.11 (2H, t, J = 6.2 Hz), 6.87 (1H, dd, J = 9.2, 2.6 Hz), 7.03 (1H, d, J = 2.6 Hz), 8.00 (1H, d, J = 9.2 Hz). LCMS (B) RT 1.01, m/z [M+H] +400/402., 132710-90-8

The synthetic route of 132710-90-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Taiho Pharmaceutical Co., Ltd.; MINAMIGUCHI, Kazuhisa; OKAJIMA, Shigeo; ASAI, Takahiro; ASAI, Masanori; OGINO, Yoshio; (80 pag.)EP3381916; (2018); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

132710-90-8, 1-Boc-4-(3-hydroxypropyl)piperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Procedure A2a: 0.61 ml (3.07 mmol) of diisopropyl diazene-1,2-dicarboxylate is added drop by dr op at 0 C. under argon to 0.5 g (2.05 mmol) of tert-butyl 4-(3-hydroxypropyl)piperazine-1-carboxylate, 0.3 g (2.46 mmol) of 4-hydroxybenzaldehyde and 1 g (3.07 mmol) of supported triphenylphosphine (3 mmol/g of resin) diluted in 14.5 ml of anhydrous tetrahydrofuran. The reaction mixture is stirred at room temperature for 20 hours, and then the solid is filtered and rinsed with dichloromethane. The filtrate is concentrated and diluted in sodium hydroxide solution (1 M), the product is extracted several times with ethyl acetate, and then the organic phases are combined, dried on magnesium sulfate and concentrated. The residue is purified by silica gel chromatography (eluent: 4:6 cyclohexane/ethyl acetate to 100% ethyl acetate) to yield 0.58 g of tert-butyl 4-(3-(4-formylphenoxy)propyl)piperazine-1-carboxylate in the form of a colorless oil. LCMS (ESI, m/z): (M+1) 348.9 1H NMR: deltaH pm 400 MHz, DMSO: 9.87 (1H, s, CHO), 7.86 (2H, d, CHarom), 7.12 (2H, d, CHarom), 4.13 (2H, t, CH2), 3.28-3.31 (4H, m, 2CH2), 2.44 (2H, t, CH2), 2.31-2.34 (4H, m, 2CH2), 1.91 (2H, q, CH2), 1.40 (9H, s, 3CH3).

132710-90-8, The synthetic route of 132710-90-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; PIERRE FABRE MEDICAMENT; Rabot, Remi; Bedjeguelal, Karim; Kaloun, El Bachir; Schmitt, Philippe; Rahier, Nicolas; Mayer, Patrice; Fournier, Emmanuel; US2014/31362; (2014); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.132710-90-8,1-Boc-4-(3-hydroxypropyl)piperazine,as a common compound, the synthetic route is as follows.,132710-90-8

A mixture of tert-butyl 4-(3-hydroxypropyl)piperazine-l-carboxylate (1.52 g, 6.2 mmol), Ph3P (2.46 g, 9.4 mmol), I2 (2.40 g, 9.4 mmol) and imidazole (1.28 g, 18.6 mmol) in DCM (100 mL) was stirred at room temperature for 5 h. The mixture was diluted with DCM and the organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and evaporated under vacuum to give a residue which was purified by column chromatography (silica gel, PE : EtOAc = 5 : 1) to afford tert-butyl 4-(3-iodopropyl)piperazine-l-carboxylate (1.10 g, 50% ) as a colorless oil.

The synthetic route of 132710-90-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; PRINCIPIA BIOPHARMA INC.; BRAMELD, Kenneth Albert; VERNER, Erik; (122 pag.)WO2016/191172; (2016); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

132710-90-8, 1-Boc-4-(3-hydroxypropyl)piperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Preparation of tert-butyl 4-[3-[4-(piperidin-4-yl)phenoxy]propyl]piperazine-l- carboxylate; DIAD (5.20 mL, 26.39 mmol) was added dropwise to benzyl 4-(4-hydroxyphenyl)-5,6- dihydropyridine-l(2H)-carboxylate (6.80 g, 21.99 mmol), tert-butyl 4-(3- hydroxypropyl)piperazine-l-carboxylate (5.91 g, 24.19 mmol) and triphenylphosphine (6.92 g, 26.39 mmol) in THF (100 mL) under nitrogen. The resulting solution was stirred at ambient temperature for 3 hours. The reaction mixture was evaporated to dryness then the residues were dissolved in ether (50 mL) and stirred for 10 minutes at ambient temperature. The resulting precipitate was removed by filtration. The filtrate was washed with water (50 mL) and saturated brine (50 mL), then dried over MgSO4, filtered and evaporated. The residue was dissolved in DCM (50 mL) and the solution was washed with 2M NaOH (50 mL), followed by saturated brine (50 mL), then dried over MgSO4, filtered, evaporated and purified by flash silica chromatography, elution gradient 30 to 70% ethyl acetate in isohexane. Fractions were evaporated to a gum, which was dissolved in MeOH (150 mL) and stirred with 5% palladium on carbon (50% wet, 1.907 g, 0.45 mmol) under an atmosphere of hydrogen at 5 bar and 25C for 16 hours. The catalyst was removed by filtration, washed with MeOH and the solvents were evaporated to give crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 10% 2M ammonia in methanol in DCM. Fractions containing the desired product were evaporated to dryness to give tert-butyl 4-[3-[4-(piperidin-4-yl)phenoxy]propyl]piperazine- 1-carboxylate (4.95 g, 56%) as a solid.IH NMR (399.9 MHz, CDC13) delta 1.46 (9H, s), 1.60 (2H, m), 1.81 (2H, m), 1.95 (2H, m), 2.40 (4H, m), 2.50 – 2.59 (3H, m), 2.73 (2H, m), 3.18 (2H, m), 3.43 (4H, m), 4.00 (2H, t), 6.84 (2H, d), 7.12 (2H, d); m/z = 404 [M+H]+.

132710-90-8, 132710-90-8 1-Boc-4-(3-hydroxypropyl)piperazine 16217800, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; BRADBURY, Robert, Hugh; CARR, Gregory, Richard; RABOW, Alfred, Arthur; RAO KORUPOJU, Srinivasa; TUMMA, Harikrishna; WO2010/92371; (2010); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.132710-90-8,1-Boc-4-(3-hydroxypropyl)piperazine,as a common compound, the synthetic route is as follows.

e-1 – carboxylate0.61 ml (3.07 mmol) of diisopropyl diazene-l,2-dicarboxylate is added drop by d r o p a t 0 C under argon to 0.5 g (2.05 mmol) of tert-butyl 4-(3- hydroxypropyl)piperazine-l -carboxylate, 0.3 g (2.46 mmol) of 4-hydroxybenzaldehyde and 1 g (3.07 mmol) of supported triphenylphosphine (3 mmol/g of resin) diluted in 14.5 ml of anhydrous tetrahydrofuran. The reaction mixture is stirred at room temperature for 20 hours, and then the solid is filtered and rinsed with dichloromethane. The filtrate is concentrated and diluted in sodium hydroxide solution (1 M), the product is extracted several times with ethyl acetate, and then the organic phases are combined, dried on magnesium sulfate and concentrated. The residue is purified by silica gel chromatography (eluent: 4:6 cyclohexane/ethyl acetate to 100% ethyl acetate) to yield 0.58 g of tert-butyl 4-(3-(4-formylphenoxy)propyl)piperazine-l -carboxylate in the form of a colorless oil.LCMS (ESI, m/z): (M+l) 348.91H MR: 6H pm 400 MHz, DMSO: 9.87 (1H, s, CHO), 7.86 (2H, d, CHarom), 7.12 (2H, d, CHarom), 4.13 (2H, t, CH2), 3.28-3.31 (4H, m, 2CH2), 2.44 (2H, t, CH2), 2.31-2.34 (4H, m, 2CH2), 1.91 (2H, q, CH2), 1.40 (9H, s, 3CH3)., 132710-90-8

132710-90-8 1-Boc-4-(3-hydroxypropyl)piperazine 16217800, apiperazines compound, is more and more widely used in various fields.

Reference£º
Patent; PIERRE FABRE MEDICAMENT; RABOT, Remi; BEDJEGUELAL, Karim; KALOUN, El Bachir; SCHMITT, Philippe; RAHIER, Nicolas; MAYER, Patrice; FOURNIER, Emmanuel; WO2012/140114; (2012); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

132710-90-8, 1-Boc-4-(3-hydroxypropyl)piperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,132710-90-8

The 6- {4-[4-(3-piperazin- 1 -ylpropoxy)phenyl]piperazin- 1 -yl} -3-(trifluoromethyl)-7,8- dihydro[l,2,4]triazolo[4,3-b]pyridazine used as starting material was prepared as follows:-; Preparation of tert-butyl 4-[3-(4-{4-[3-(trifluoromethyl)[l,2,4]triazolo[4,3- b]pyridazin-6-yl]piperazin-l-yl}phenoxy)propyl]piperazine-l-carboxylate; DIAD (3.24 mL, 16.47 mmol) was added dropwise to 4-{4-[3- (trifluoromethyl)[ 1 ,2,4]triazolo[4,3-b]pyridazin-6-yl]piperazin- 1 -yl}phenol (obtained as described in Example 16, preparation of starting materials) (5 g, 13.72 mmol), tert-butyl 4- (3-hydroxypropyl)piperazine-l-carboxylate (CAS 132710-90-8, 5.03 g, 20.59 mmol) and triphenylphosphine (5.40 g, 20.59 mmol) in THF (50 mL) at 00C under nitrogen. The resulting solution was stirred at ambient temperature for 16 hours. The reaction mixture was evaporated to dryness and redissolved in DCM (100 mL), and washed sequentially with 2M NaOH (100 mL) and saturated brine (100 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, eluting with EtOAc. Pure fractions were evaporated to dryness to give tert-butyl 4-[3-(4-{4-[3-(trifluoromethyl)[l,2,4]t?azolo[4,3-b]pyridazin-6- yl]piperazin-l-yl}phenoxy)propyl]piperazine-l-carboxylate (3.66 g, 45%). IH NMR (399.9 MHz, CDC13) delta 1.46 (9H, s), 1.95 (2H, m), 2.40 (4H, m), 2.52 (2H, t), 3.21 (4H, m), 3.43 (4H, m), 3.78 (4H, m), 3.99 (2H, t), 6.87 (2H, d), 6.93 (2H, d), 7.11 (IH, d), 7.96 (IH, d); m/z = 591 [M+H]+.

As the paragraph descriping shows that 132710-90-8 is playing an increasingly important role.

Reference£º
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; BRADBURY, Robert, Hugh; CARR, Gregory, Richard; RABOW, Alfred, Arthur; RAO KORUPOJU, Srinivasa; TUMMA, Harikrishna; WO2010/92371; (2010); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.132710-90-8,1-Boc-4-(3-hydroxypropyl)piperazine,as a common compound, the synthetic route is as follows.

To 0.5 g (2.05 mmol) of tert-butyl 4-(3-hydroxypropyl)piperazine-1-carboxylate, 0.3 g (2.46 mmol) of 4-hydroxybenzaldehyde and 1 g (3.07 mmol) of resin-supported triphenyl-phosphine (3 mmol/g of resin) diluted in 14.5 ml of anhydrous tetrahydrofuran, is added dropwise at 0C under argon 0.614 ml (3.07 mmol) of diisopropyldiazene-1,2-dicarboxylate. The reaction mixture is stirred at room temperature for 20h. The solid is filtered then rinsed in dichloromethane. The filtrate is concentrated and diluted in a sodium hydroxide solution (1M) and the product is extracted several times with ethyl acetate. The organic phases are combined, dried over magnesium sulfate, and concentrated. The residue is purified by chromatography on silica (cyclohexane/ethyl acetate eluent: 4:6 to 100% ethyl acetate) to yield 0.58 g of tert-butyl 4-(3-(4-formylphenoxy)propyl)piperazine-l-carboxylate in the form of a colourless oil.LCMS (ESI, m/z): (M+l) 348.91H-NMR: deltaEta pm 400 MHz, DMSO: 9.87 (1H, s, CHO), 7.86 (2H, d, CH^), 7.12 (2H, d, CHaro , 4.13 (2H, t, CH2), 3.28-3.31 (4H, m, 2CH2), 2.44 (2H, t, CH2),2.31-2.34 (4H, m, 2CH2), 1.91 (2H, q, CH2), 1.40 (9H, s, 3CH3).

132710-90-8, As the paragraph descriping shows that 132710-90-8 is playing an increasingly important role.

Reference£º
Patent; PIERRE FABRE MEDICAMENT; BEDJEGUELAL, Karim; RABOT, Remi; KALOUN, El Bachir; MAYER, Patrice; MARCHAND, Arnaud; RAHIER, Nicolas; SCHAMBEL, Philippe; BIENAYME, Hugues; WO2011/45344; (2011); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics